{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:06:00Z","timestamp":1761541560682,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.brachy.2020.06.017","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T16:22:21Z","timestamp":1599841341000},"page":"584-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost"],"prefix":"10.1016","volume":"19","author":[{"given":"Ibtihel","family":"Ben Aicha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Hathout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3086-2010","authenticated-orcid":false,"given":"Damien","family":"Carignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Despr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylviane","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-5653","authenticated-orcid":false,"given":"William","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9-Guy","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Vigneault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2020.06.017_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.06.017_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.06.017_bib3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2014.06.031","article-title":"Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: Implications for establishing new dose constraints for treatment planning","volume":"90","author":"Hathout","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.06.017_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.radonc.2013.07.019","article-title":"Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?","volume":"109","author":"Steggerda","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.06.017_bib5","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1259\/bjr\/15403217","article-title":"High dose rate prostate brachytherapy: An overview of the rationale, experience and emerging applications in the treatment of prostate cancer","volume":"85","author":"Challapalli","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.brachy.2020.06.017_bib6","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.ijrobp.2011.08.002","article-title":"External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: Preliminary data on clinical outcome","volume":"82","author":"Mart\u00ednez-Monge","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.06.017_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5114\/jcb.2018.76980","article-title":"Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: Patient reported quality of life outcomes","volume":"10","author":"Morgan","year":"2018","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2020.06.017_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clon.2014.06.012","article-title":"Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy","volume":"26","author":"Choudhury","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.brachy.2020.06.017_bib9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ctrv.2013.10.006","article-title":"High dose rate brachytherapy boost for prostate cancer: A systematic review","volume":"40","author":"Zaorsky","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.brachy.2020.06.017_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-Term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.06.017_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.06.017_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost f","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.06.017_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.06.017_bib14","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1200\/JCO.2016.72.0466","article-title":"Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology\/Cancer Care Ontario joint guideline update","volume":"35","author":"Chin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2020.06.017_bib15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0022-5347(01)62542-4","article-title":"Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate","volume":"160","author":"Terk","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2020.06.017_bib16","first-page":"1597","article-title":"Predictive factors of urinary retention following prostate brachytherapy","volume":"169","author":"Bucci","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.06.017_bib17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.brachy.2019.06.001","article-title":"High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores","volume":"18","author":"Morgan","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.06.017_bib18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1590\/S1677-5538.IBJU.2014.0289","article-title":"Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes","volume":"41","author":"Yang","year":"2015","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.brachy.2020.06.017_bib19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clon.2017.01.042","article-title":"Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer","volume":"29","author":"Shahid","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.brachy.2020.06.017_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijrobp.2013.10.042","article-title":"Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"88","author":"Ghadjar","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.06.017_bib21","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.brachy.2017.05.009","article-title":"Focal brachytherapy for localized prostate cancer: Urinary toxicity depends on tumor location","volume":"16","author":"Srougi","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.06.017_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.brachy.2019.02.003","article-title":"Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life","volume":"18","author":"Sanmamed","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.06.017_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.adro.2019.04.003","article-title":"A phase II randomized pilot study comparing high-dose rate brachytherapy and low-dose rate brachytherapy as monotherapy in localized prostate cancer","volume":"4","author":"Hathout","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.06.017_bib24","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ijrobp.2007.11.067","article-title":"Virtual HDRSM CyberKnife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations","volume":"70","author":"Fuller","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472120301355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472120301355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:15:45Z","timestamp":1761531345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472120301355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1538472120301355"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2020.06.017","relation":{},"ISSN":["1538-4721"],"issn-type":[{"type":"print","value":"1538-4721"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2020.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}